Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 5:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo - IV Clear all
Terminated Phase 2 Interventional Results available

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

NCT00808210
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Infliximab, Methotrexate, Methylprednisolone, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 22, 2026, 5:42 AM EDT
Completed Phase 3 Interventional Results available

The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial

NCT01690988
View directory record Official record
Conditions
Delirium
Interventions
Ketamine (0.5 mg/kg), Normal Saline (placebo), Ketamine (1 mg/kg)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 22, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.

NCT01920854
View directory record Official record
Conditions
Kidney Failure, Chronic Therapy; Hemodialysis
Interventions
soluble ferric pyrophosphate, Placebo
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 22, 2026, 5:42 AM EDT
Terminated Phase 2 Interventional Results available

Proof of Concept (POC) in Patients With Ischaemic Stroke

NCT01808261
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
GSK249320 100/mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 90 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
Orange, California • Jacksonville, Florida • Peoria, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 22, 2026, 5:42 AM EDT
Withdrawn Phase 1 Interventional

Autologous Cell Therapy After Stroke

NCT00908856
View directory record Official record
Conditions
Stroke
Interventions
autologous bone marrow mononuclear cell transfusion, marrow stromal cells, placebo
Biological · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 22, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects

NCT01291602
View directory record Official record
Conditions
Healthy Male and Female Japanese Volunteers
Interventions
NXL104, CAZ104, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
20 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 22, 2026, 5:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Furosemide on Confirmation of Ureteral Patency During Routine Cystoscopy

NCT02960412
View directory record Official record
Conditions
Cystoscopy
Interventions
furosemide, Normal Saline
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Sep 22, 2026, 5:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer

NCT01016483
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Pimasertib, Gemcitabine, Placebo
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Sep 22, 2026, 5:42 AM EDT
Completed Phase 3 Interventional

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

NCT02500381
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
SRP-4045, SRP-4053, Placebo
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
6 Years to 13 Years · Male only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 22, 2026, 5:42 AM EDT
Completed Not applicable Interventional Results available

Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation

NCT01014741
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
Ibutilide, Placebo
Drug
Lead sponsor
Vivek Reddy
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
Sacramento, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 22, 2026, 5:42 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH

NCT00296465
View directory record Official record
Conditions
InFertility
Interventions
Pulsatile gonadotropin-releasing hormone (GnRH), Clomiphene Citrate, Placebo Pulsatile GnRH, Placebo Clomiphene Citrate
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated May 18, 2011 · Synced Sep 22, 2026, 5:42 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Secretin in Functional Dyspepsia and Healthy Subjects

NCT03617861
View directory record Official record
Conditions
Dyspepsia, Healthy
Interventions
Human Secretin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 22, 2026, 5:42 AM EDT
Completed Phase 3 Interventional Results available

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

NCT02510261
View directory record Official record
Conditions
Amyloidosis
Interventions
Patisiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
14
States / cities
La Mesa, California • Aurora, Colorado • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 22, 2026, 5:42 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis

NCT00727194
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
eculizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
21
States / cities
Birmingham, Alabama • Orange, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 22, 2026, 5:42 AM EDT
Not listed Not applicable Interventional

Efficacy of IV Acetaminophen in Acute Post-Operative Pain Control in Laparoscopic Roux-en-Y Gastric Bypass Surgery (LRYGBP) Patients

NCT01460667
View directory record Official record
Conditions
Morbid Obesity
Interventions
IV acetaminophen, IV normal saline
Drug
Lead sponsor
McLaren Regional Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 26, 2011 · Synced Sep 22, 2026, 5:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ondansetron Reduce Vomiting Associated With Ketamine PSA

NCT00387556
View directory record Official record
Conditions
Conscious Sedation
Interventions
Ondansetron
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Year to 21 Years
Enrollment
268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 12, 2013 · Synced Sep 22, 2026, 5:42 AM EDT
Completed Phase 1 Interventional

CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function

NCT02071602
View directory record Official record
Conditions
ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
Interventions
CD-NP
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 22, 2026, 5:42 AM EDT
Completed Phase 4 Interventional

A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy

NCT01661166
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Fesoterodine, Placebo oral tablet
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
30 Years to 90 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Sep 22, 2026, 5:42 AM EDT
Terminated Phase 4 Interventional Results available

Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU

NCT02343575
View directory record Official record
Conditions
Hyperactive Delirium, Mixed Delirium
Interventions
Valproic Acid, Placebo, Haloperidol
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Sep 22, 2026, 5:42 AM EDT
Terminated Phase 2 Interventional Results available

IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis

NCT02241512
View directory record Official record
Conditions
Post-ERCP Acute Pancreatitis
Interventions
Ibuprofen, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 18 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Sep 22, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Results available

Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children

NCT02707523
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Azithromycin 10 mg, Azithromycin 20mg, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 16 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 22, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxygen Levels in Healthy Volunteers

NCT04808622
View directory record Official record
Conditions
Healthy Subjects
Interventions
Trans-Sodium Crocetinate, Placebo
Drug
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Sep 22, 2026, 5:42 AM EDT
Completed Phase 3 Interventional Results available

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

NCT00094653
View directory record Official record
Conditions
Melanoma, Metastases
Interventions
MDX-010 (anti-CTLA4) monoclonal antibody, MDX-1379 (gp100) Melanoma Peptide Vaccine
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,783 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
110
States / cities
Tucson, Arizona • Duarte, California • Encinitas, California + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2011 · Synced Sep 22, 2026, 5:42 AM EDT